One more thing to think about. If leronlimab is priced reasonably, and can target a large number of cancers and dramatically reduce metastasis and increase chemo potency, it might reduce the need for other expensive and expensive to regularly administer cancer drugs and maybe give patients more options with relatively more affordable radiotherapy and surgery. Therefore, even though leronlimab would generate large revenues, it might still actually be long term cost neutral or only slightly cost positive in terms of overall healthcare spending. That is also why I have not been that impressed with the current CART bandwagon that costs upwards of 400k a patient per treatment with regards to sustainability